Shares of Gelteq Limited (NASDAQ: GELS) experienced a dramatic rally on Thursday, with the stock surging approximately 56% to $0.805 as of 1:49 PM ET. The biotech firm's shares traded as low as $0.5145 earlier in the session before spiking to an intraday high of $2.01, marking a volatile trading day that triggered multiple volatility pauses on the Nasdaq.
Massive Volume Spike
Trading volume for Gelteq shares exceeded 106 million shares, a staggering increase compared to the stock's recent average daily volume of approximately 36,040 shares since its listing. This volume surge coincided with sharp price swings that led the Cboe to post several “Volatility Pause” entries for GELS, starting at 11:12:36 AM ET and continuing until at least 1:17:37 PM ET.
These trading halts are part of the Limit Up-Limit Down (LULD) mechanism, which pauses trading in NMS stocks when prices move outside set bands. Under LULD rules, a stock that remains in a limit state for more than 15 seconds triggers a five-minute pause by the primary listing exchange. According to Nasdaq Trader, a “T5” pause occurs when a security moves 10% or more in price over five minutes, leading to a single-stock trading halt.
Catalysts Behind the Rally
The sharp move higher comes on the heels of several recent corporate announcements. On June 4, Gelteq announced the establishment of a new Center of Excellence in Guangdong Province, China. The facility is expected to support product development, testing, formulation, and other commercial activities. This news follows a series of operational updates, including the May 20 announcement of the initiation of its first clinical trial for an antiparasitic drug candidate, which utilizes Gelteq's proprietary gel-based delivery technology and is designed to support an FDA regulatory pathway for animal health applications.
Additionally, on May 12, Gelteq disclosed up to $3.5 million in strategic debt financing to fund commercialization efforts, clinical trial costs, and revenue-generating activities. A subsequent SEC filing on May 26 detailed a securities purchase agreement with an institutional investor for up to $3.5 million in two tranches. The first tranche delivered $1.0 million after a $150,000 original issue discount, structured as a convertible promissory note with a principal of $1.165 million, bearing 7% annual interest and an 18-month maturity.
Market Context and Compliance Concerns
Gelteq's trading activity stood out against a broadly positive market backdrop. The Nasdaq Composite gained 1.82% to 25,628.30, while the S&P 500 added 1.31% and the Dow Jones Industrial Average rose 1.67% during the same period.
Despite the rally, Gelteq remains in a minimum-bid-price grace period from Nasdaq. A Form 6-K filed on March 24 revealed that Nasdaq had notified the company that its stock had closed below $1.00 for 30 consecutive business days. Gelteq has until September 14, 2026, to regain compliance by achieving a closing bid price of at least $1.00 for 10 consecutive business days.
Outlook
Gelteq, a Melbourne-based biotechnology company, specializes in gel-based delivery technologies for pharmaceutical, consumer health, and animal health markets. While the stock has pulled back significantly from its intraday high of $2.01, it remains well above Wednesday's close. Traders are closely monitoring the stock's closing price, trading volume, and any further announcements from the company's investor relations page.
